Sun Radiology Refer a Friend Program

May 3, 2013 | Posted in News | By | Leave a Comment

Give a Sun Radiology Refer a Friend Card to a Friend and if they complete an exam with us you both may win our monthly prize drawing.

Sun Radiology Leads Arizona in Diagnosing Alzheimer’s Disease

May 3, 2013 | Posted in News, Press Release | By | Leave a Comment

SUN RADIOLOGY, the leader in neurological molecular imaging, continues their commitment to lead the way in molecular imaging by being the FIRST in the United States to perform the Alzheimer’s (Amyvid) PET/CT scan to detect Alzheimer’s dementia. SUN RADIOLOGY is the first to offer the Amyvid PET/CT exam in Arizona with a comprehensive neuropsychological testing .

Amyvid (Beta Amyloid Plaque) PET/CT  is indicated for imaging of the brain to estimate beta amyloid plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. It is the first and only FDA approved diagnostic PET tracer for imaging amyloid plaques in the living human brain. This new diagnostic tool will drastically change the management of Alzheimer’s dementia. The Amyvid PET/CT will now allow us to for the first time to diagnose Alzheimer’s Dementia with an imaging test and will allow us to find a cure for this terrible disesaes. SUN RADIOLOGY is commited to ending Alzheimer’s dementia by 2020. 

SUN RADIOLOGY has several  full modality imaging centers throughout the valley. Sun Radiology’s specialty is detecting diseases earlier on a molecular level.

FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer’s Disease and Other Causes of Cognitive Decline

Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain

INDIANAPOLIS, April 6, 2012 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes of cognitive decline.[1] Amyvid binds to amyloid plaques, a hallmark characteristic of Alzheimer’s Disease,[2],[3],[4] and is detected using PET scan images of the brain.[1]

Read more…